Navigation Links
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Date:12/4/2010

Poster III  
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-383

  • Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia

    • Presenter: Gillian Stephens, Ph.D., Portola Pharmaceuticals
    • Poster Session: Pathophysiology of Thrombosis: Poster II
    • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
    • Location: Hall A3/A4 (Orange County Convention Center)
    • Poster Board III-997

    About Portola Pharmaceuticals, Inc.

    Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible direct-acting i.v. and oral P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care antiplatelet and anticoagulant markets.

    Portola's proprietary pipeline programs are focused on the discovery and development of PRT064445, a novel recombinant protein anticoagulant antidote, known as the Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in
    '/>"/>

    SOURCE Portola Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
    2. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
    3. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
    4. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
    5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
    6. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
    7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
    8. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
    9. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
    10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
    11. Onyx Pharmaceuticals Announces December 2010 Investor Events
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... , June 29, 2015  Daktari Diagnostics was honored at ... Technology in the Service of Society Award. IEEE President and ... Barry L. Shoop presented the award to Principal Scientist ... ceremony was held Saturday, June 20, 2015, at the historic ... . "I have spent more than 3 ...
    (Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
    (Date:6/29/2015)... Nev. , June 29, 2015  PDL BioPharma, ... has entered into a credit agreement with CareView Communications, ... up to $40 million of secured debt financing. CareView ... focused on patient care monitoring. Under the ... $40 million of debt financing in two tranches of ...
    Breaking Medicine Technology:Daktari Honored with IEEE Spectrum Award 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4
    ... Oct. 24, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ... & Drug Administration (FDA) has scheduled a meeting of ... 2011, at which the ADASUVE New Drug Application (NDA) ... that the FDA had accepted the resubmission of the ...
    ... 2011 Covance Inc. (NYSE: CVD ) ... Shanghai, China, has received Good Laboratory Practice (GLP) certification ... the Organization for Economic Cooperation and Development (OECD). The ... toxicology, in-vivo PK screening, and metabolism services. ...
    Cached Medicine Technology:Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 2Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 3Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China 2
    (Date:6/29/2015)... NEW YORK (PRWEB) , ... June 29, 2015 ... ... apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device ... Administration and is an alternative to continuous positive airway pressure (CPAP), the current ...
    (Date:6/29/2015)... ... June 29, 2015 , ... Human Factors ... Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors ... human factors engineering to the design of new products as well as to ...
    (Date:6/29/2015)... , ... June 29, 2015 , ... ... developed a new approach to build nearly complete genomes by combining high-throughput DNA ... genomic variation, critically important for their association with human disease, but previously difficult ...
    (Date:6/29/2015)... OH (PRWEB) , ... June 29, 2015 , ... ... support to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, ... President and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief ...
    (Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the launch of an ... well as a redesigned logo and weekly eLetter. The website contains the same informational ... and easier to navigate. , In addition to a refreshed look, http://www.ormanager.com ...
    Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2
    ... By Jenifer Goodwin HealthDay Reporter , ... a good predictor of academic performance, but not necessarily ... tested the IQs and reading, spelling and math abilities ... the children,s social functioning through parental and teacher reports ...
    ... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) ... the year, many Americans will soon be subjected to radiation-emitting ... tide of concerns and complaints in recent weeks over body ... is too low to pose any serious health threat. ...
    ... 2010) - Even though most people are aware that good ... mother and child, misunderstandings about the safety of dental care ... dentist. The fact is that dentists can create a treatment ... adverse effects of oral disease during pregnancy. During the ...
    ... Reporter , TUESDAY, Nov. 23 (HealthDay News) -- Being born just ... child,s IQ and ability to pay attention, new research suggests. ... to those born between 34 to 36 weeks (called "late ... twice the risk of having an IQ score below 85 and ...
    ... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... antioxidant cousin, alpha-carotene, in fruits and vegetables can lower ... disease and cancer, new research suggests. Both ... because of the red, yellow and orange coloring they ...
    ... , TUESDAY, Nov. 23 (HealthDay News) ... and efficiency while preventing sudden death among heart ... survival in real-world situations as they are in ... finding is based on an analysis of nearly ...
    Cached Medicine News:Health News:For Autistic Kids, IQ May Not Predict School Achievement 2Health News:For Autistic Kids, IQ May Not Predict School Achievement 3Health News:Airport Body Scanners Safe, Experts Say 2Health News:Airport Body Scanners Safe, Experts Say 3Health News:Expecting? Don't neglect your teeth 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 3Health News:Eat Your Fruits & Veggies for Longer Life 2Health News:Eat Your Fruits & Veggies for Longer Life 3Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: